| Assessment Status |
NCPE Assessment Process Complete |
| HTA ID |
- |
| Drug |
Apixaban |
| Brand |
Eliquis® |
| Indication |
For the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. |
| Rapid review commissioned |
19/10/2021 |
| Rapid review completed |
02/11/2011 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
01/02/2012 |
| NCPE assessment completed |
19/06/2012 |
| NCPE assessment outcome |
The NCPE believe that apixaban is cost effective for the prevention of VTE following total hip replacement and total knee replacement. |
